Regeneron Pharmaceuticals Inc. buy TD Cowen
Summary
This prediction ended on 24.07.25 with a price of €487.20. The BUY prediction by TD_Cowen for Regeneron Pharmaceuticals Inc. performed very badly with a performance of -50.36%. Dividends of €1.72 are taken into consideration when calculating the performance. TD_Cowen has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -6.440% | -6.440% | -17.947% |
| iShares Core DAX® | 1.917% | 1.088% | 17.187% |
| iShares Nasdaq 100 | 0.911% | 1.674% | 7.930% |
| iShares Nikkei 225® | 0.833% | -1.712% | 12.100% |
| iShares S&P 500 | 0.242% | 1.258% | 3.167% |
Comments by TD_Cowen for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by TD_Cowen for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
24.04.24
24.04.25
25.04.25
Regeneron Pharmaceuticals Inc.
06.12.23
06.12.24
07.12.24

